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Abstract: Drug delivery of immunotoxins to brain tumors circumventing the blood brain 
barrier is a significant challenge. Convection-enhanced delivery (CED) circumvents the 
blood brain barrier through direct intracerebral application using a hydrostatic pressure 
gradient to percolate therapeutic compounds throughout the interstitial spaces of infiltrated 
brain  and  tumors.  The  efficacy  of  CED  is  determined  through  the  distribution  of  the 
therapeutic agent to the targeted region. The vast majority of patients fail to receive a 
significant amount of coverage of the area at risk for tumor recurrence. Understanding this 
challenge, it is surprising that so little work has been done to monitor the delivery of 
therapeutic  agents  using  this  novel  approach.  Here we present a  review of imaging  in 
convection  enhanced  delivery  monitoring  of  toxins  in  humans,  and  discuss  future 
challenges in the field. 
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1. Introduction 
Glioblastoma multiforme (GBM) continues to have a poor prognosis despite aggressive surgical 
resection and recent advances in radiotherapy and chemotherapy. The median survival after diagnosis 
of GBM is 14 months [1]. Drug delivery to GBM has been particularly challenging and accounts for 
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some of the difficulty in treating this disease.
 Since Ehrlich first described the characteristics of blood 
brain barrier in 1885, it has been known that systemic drugs have limited penetration into the central 
nervous system. Our current therapeutic options continue to be limited with non-targeted systemic or 
intrathecal  delivery  that  have  side  effects  of  system  toxicity,  injury  to  surrounding  tissues,  and 
suboptimal drug delivery to the tumor site. The blood brain barrier in particular impedes the delivery 
of systemically delivered chemotherapeutics by hindering the ability of these agents to cross from the 
circulation  into  the  tumor  cells  within  the  brain  [2].  In  addition,  the  highly  invasive  character  of 
malignant  brain  tumors  confounds  our  ability  to  effectively  target  these  diseased  tissues  using 
conventional surgical resection and radiation therapy. 
Convection-enhanced  delivery  (CED)  circumvents  the  blood  brain  barrier  through  direct 
intracerebral  application  using  a  hydrostatic  pressure  gradient  to  percolate  therapeutic  compounds 
throughout  the  interstitial  spaces  of  infiltrated  brain  and  tumors  (Figure  1)  [3].  Convection 
supplements diffusion to greatly enhance distribution of small and large molecular therapeutics [3]. 
CED also theoretically capitalizes on the presence of an intact blood brain barrier given the advantage 
of limited egress of therapeutic agent out of the brain, which serves to both enhance drug delivery 
while  reducing  the  risk  of  systemic  toxicity  in  humans.  CED  has  a  unique  property  wherein  the 
distribution of therapeutic drug is pressure driven. This phenomena allows for a relatively constant 
concentration  of  the  immunotoxins  for  a  predictable  distance  before  a  drop-off  [4],  thus  limiting 
neurotoxicity yet providing effective drug therapy to the tumor upon accurate catheter placement [5].  
Figure  1.  A  model  of  convection  enhanced  delivery.  Catheters  are  placed  into  the 
enhancing tumor to cover the region of effect.  
 
The efficacy of CED is determined through the distribution of the therapeutic agent to the targeted 
region at a sufficient concentration. Catheter placement has been previously noted to have a dramatic 
effect  on  drug  delivery  [5,6]  given  that  leakage  of  infusate  into  the  interventricular  spaces  and 
subarachnoid results in poor drug delivery and distribution [6]. Clinical and preclinical studies have 
been utilized to determine distribution and delivery of drug into the brain but use differing imaging 
modalities  (MRI,  single  photon  emission  computed  tomography  (SPECT))  and  are  mostly  animal 
studies that fail to replicate drug distribution in humans [6–9]. Despite the use of rigorous guidelines Toxins 2011, 3                                       203 
and computer simulations, the vast majority of patients fail to receive a significant amount of coverage 
of the area at risk for tumor recurrence.  
Understanding  this  challenge,  it  is  surprising  that  so  little  work  has  been  done  to  monitor  the 
delivery of therapeutic agents using this novel approach. Here we present a review of imaging in 
convection  enhanced  delivery  monitoring  of  toxins  in  humans,  and  discuss  future  challenges  in 
the field. 
2. In Vivo Imaging of CED Infusate Distribution 
The theoretical benefit  of pressure-driven infusion is the enhanced distribution of a therapeutic 
agent  at  higher  concentrations  than  would  typically  be  achieved  by  diffusion  alone.  While 
mathematical models may predict drug transport as a function of patient-specific parameters, the data 
needed to validate these models in a noninvasive and real-time fashion can only be obtained with 
techniques that allow one to measure tissue concentration of a given particle in vivo.  
Based largely on indirect measures, many currently available approaches for tracking CED-infused 
therapies in vivo rely on radiographic alterations that occur as a result of either fluid administration or 
drug-induced effects on tissue. However, as CED continues to gain prominence as a drug delivery 
platform, the need for more accurate methods of validation will be necessary to objectively assess this 
approach as an effective means to achieving therapeutic concentrations of a drug in an appropriate 
target region. 
3. Albumin-Conjugated Surrogate Tracers 
The  use  of  albumin-linked  surrogate  tracers  has  been  shown  in  a  number  of  studies  to  model 
macromolecular distribution via CED in the primate brain. When linked to either iopanoic acid (IPA) 
or Gd-diethylenetriamine pentaacetic acid (DTPA), CED-infused albumin tracers can be visualized 
using conventional noninvasive imaging modalities, CT and MRI respectively. Studies comparing the 
distribution volume of infused Gd-DPTA-albumin and IP-albumin to that of 
14C-labeled albumin, as 
measured by quantitative autoradiography (QAR), have concluded that clinically relevant volumes of 
macromolecular substrate could be achievable in the brain using the CED approach [10].  
4. MRI Imaging T2 Imaging Changes 
More recent investigations have demonstrated that changes in T2-weighted MRIs after treatment in 
humans can also be used to accurately assess the volume of distribution for therapies administered via 
CED. By employing T2-weighted MR in combination with SPECT imaging, Sampson et al. showed 
that  three  separate  reviewers  were  able  to  consistently  predict  intraparenchymal  distribution  after 
observing changes in T2-weighted MRI signals 48 h post-infusion [11]. In patients with preexisting 
MRIs that showed no abnormalities, the emergence of T2 changes following infusion correlated with 
predicted  geometries  of  drug  distribution.  Furthermore,  in  patients  who  did  exhibit  preexisting 
hyperintense signals on T2-weighted MRI, visibly discernable alterations in signal shape and intensity 
were  observed.  In  this  study, 
123I-HSA  was  co-infused  as  a  surrogate  tracer  to  compare  with  T2 
changes [12], which revealed inherent limitations with T2-weighted MRI. First, patients demonstrated 
hyperintense signals on T2-weighted MRI after infusion, though these changes were indistinguishable Toxins 2011, 3                                       204 
from those due to pre-existing peritumoral edema secondary to malignant glioma [7]. A second pitfall 
with T2-weighted MRI was its inability to assess hyperintense signal in gray matter structures [7].  
T2-weighted MRI signals could be useful for determining infusate distribution to the inventricular 
space or subarachnoid space, but its limitations make this modality less than ideal for determining the 
exact location of infusate when either edema is present or when distribution assessment is attempted 
throughout gray matter.  
5. Gadolinium-Based Liposome Constructs 
Gadolinium–diethylene triamine pentaacetic acid (Gd-DTPA) is a widely available MRI contrast 
agent, however with its small molecular weight (938 Dalton) there are concerns regarding its ability to 
predict  the  distribution  of  larger  molecules  in  CED.  Due  to  this  concern,  groups  have  creatively 
applied  this  surrogate  tracer  with  some  advantage  by  incorporating  it  into  drug  impregnated 
liposomes [13]  or  by  infusing  it  into  the  brainstem  where  volumes  of  infusion  are  low  [13–16]. 
Liposome  constructs,  however,  require  complex  manufacturing  processes  and  are  also  not  widely 
available, and most tumors needing treatment are located in the supratentorial compartment. 
6. Gadolinium-Bound Albumin 
Gadolinium-bound albumin has been utilized due to its larger molecular weight (MW 72,000 D) 
and has been recently compared in distribution with Gd-DTPA (MW 590 D) at pial and ependymal 
boundaries [17]. Using a primate model, the authors demonstrated that pial and ependymal boundaries 
are  permeable  to  both  small  and  large  molecular  weighted  molecules  [17].  In  addition,  they 
demonstrated that FLAIR MR imaging was more sensitive in detecting Gd-labeled compounds into the 
CSF during CED  [17]. The results of this study  seem to  demonstrate  similar distribution  profiles 
between these agents, but are not consistent with the previous reports of smaller proteins having a 
different volume of distribution from larger capsids [18]. 
7. Gadolinium Direct Infusion  
Because  the  development  of  large  molecule  tracers  labeled  with  gadolinium  (Gd)  has  been 
problematic,  the  infusion  of  low  molecular  weight  Gd-DTPA  (Gadolinium  conjugated 
diethylenetriamine penta-acetic acid) is a commonly used MRI contrast agent which can be co-infused 
with therapies using CED to detect leak and distribution of tracer.  
We have recently demonstrated the ability to define the distribution of larger molecules by imaging 
dual  infusions  of  Gd-DTPA  with  iodinated-albumin  and  the  therapeutic  drug  (MR1-1)  [19].  We 
simultaneously  infused  patients  with  supratentorial  recurrent  malignant  gliomas  with  an  
EGFRvIII-targeted  immunotoxin  in  combination  with 
124I-HSA  (to  permit  PET  imaging)  and  
Gd-DTPA. We demonstrate that Gd-DTPA infusions provide direct information about the distribution 
of large molecules with high resolution and in combination with fluid-attenuated inversion recovery 
(FLAIR)  imaging,  provide  additional  information  about  leak  into  cerebrospinal  fluid  spaces  and  
resection cavities [19].  
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8. Conclusions 
CED-infusion  approaches  offer  a  promising  platform  for  therapy  in  patients  with  GBM.  Even 
though mathematical models are predictive of drug transport and distribution, the ability of in vivo 
imaging  to  approximate  the  anatomical  location  of  infusate  becomes  advantageous  in  both  the  
real-time monitoring and validation of clinical models. Imaging for CED has evolved from the use of 
iodine-labeled albumin tracers to direct Gadolinium infusate; however we are still on the frontier of 
discovery in validating these modalities. Since CED continues to gain prominence as a drug delivery 
platform  in  brain  tumor  patients,  the  need  for  more  accurate  methods  of  validation  grows 
commensurately.  
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